ProCE Banner Activity

Final iDFS Analysis of NATALEE: Phase III Trial of Adjuvant Ribociclib + Nonsteroidal Aromatase Inhibitor in HR+/HER2- EBC

Conference Coverage

In final protocol-specified iDFS analysis of the phase III NATALEE trial, treatment with adjuvant ribociclib + NSAI continued to show significant improvement in invasive disease-free survival (iDFS) vs NSAI alone in patients with HR+/HER2- early breast cancer (EBC).

Released: December 10, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Merck Sharp & Dohme, LLC

Seagen Inc.